BioLife Solutions (NASDAQ:BLFS) EVP Aby Mathew Sells 529 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby Mathew sold 529 shares of the company’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $20.74, for a total value of $10,971.46. Following the completion of the transaction, the executive vice president owned 392,937 shares in the company, valued at $8,149,513.38. This represents a 0.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

BioLife Solutions Stock Down 2.7%

Shares of BioLife Solutions stock traded down $0.55 during trading on Thursday, reaching $20.12. The company’s stock had a trading volume of 639,660 shares, compared to its average volume of 408,797. The firm’s 50-day moving average is $23.57 and its two-hundred day moving average is $25.13. BioLife Solutions, Inc. has a 52-week low of $19.10 and a 52-week high of $29.62. The company has a market cap of $971.80 million, a price-to-earnings ratio of -182.89 and a beta of 1.90.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Northland Securities set a $34.00 price objective on shares of BioLife Solutions in a research note on Monday, January 5th. Zacks Research upgraded shares of BioLife Solutions from a “hold” rating to a “strong-buy” rating in a report on Friday, January 23rd. HC Wainwright reissued a “buy” rating and issued a $32.00 price objective on shares of BioLife Solutions in a research note on Monday, December 29th. UBS Group reissued a “buy” rating on shares of BioLife Solutions in a research report on Monday, December 29th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioLife Solutions in a research report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $32.00.

Institutional Investors Weigh In On BioLife Solutions

Institutional investors have recently modified their holdings of the company. Global Retirement Partners LLC acquired a new position in shares of BioLife Solutions in the 4th quarter valued at $30,000. Kemnay Advisory Services Inc. acquired a new stake in BioLife Solutions in the fourth quarter valued at about $35,000. Hantz Financial Services Inc. boosted its stake in shares of BioLife Solutions by 54.1% in the third quarter. Hantz Financial Services Inc. now owns 1,877 shares of the medical equipment provider’s stock valued at $48,000 after buying an additional 659 shares in the last quarter. Quarry LP increased its holdings in shares of BioLife Solutions by 50.9% in the 3rd quarter. Quarry LP now owns 2,113 shares of the medical equipment provider’s stock valued at $54,000 after purchasing an additional 713 shares in the last quarter. Finally, Ameritas Investment Partners Inc. lifted its position in shares of BioLife Solutions by 12.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider’s stock valued at $83,000 after acquiring an additional 441 shares during the period. 93.24% of the stock is owned by hedge funds and other institutional investors.

About BioLife Solutions

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.